REVIEW

40 years of the human T-cell leukemia virus: past, present, and future [version 1; peer review: 2 approved]

Yutaka Tagaya¹, Masao Matsuoka², Robert Gallo¹

¹Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA

²Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-0811, Japan

v1 First published: 28 Feb 2019, 8(F1000 Faculty Rev):228
<https://doi.org/10.12688/f1000research.17479.1>

Latest published: 28 Feb 2019, 8(F1000 Faculty Rev):228
<https://doi.org/10.12688/f1000research.17479.1>

Abstract

It has been nearly 40 years since human T-cell leukemia virus-1 (HTLV-1), the first oncogenic retrovirus in humans and the first demonstrable cause of cancer by an infectious agent, was discovered. Studies indicate that HTLV-1 is arguably one of the most carcinogenic agents to humans. In addition, HTLV-1 causes a diverse array of diseases, including myelopathy and immunodeficiency, which cause morbidity and mortality to many people in the world, including the indigenous population in Australia, a fact that was emphasized only recently. HTLV-1 can be transmitted by infected lymphocytes, from mother to child via breast feeding, by sex, by blood transfusion, and by organ transplant. Therefore, the prevention of HTLV-1 infection is possible but such action has been taken in only a limited part of the world. However, until now it has not been listed by the World Health Organization as a sexually transmitted organism nor, oddly, recognized as an oncogenic virus by the recent list of the National Cancer Institute/National Institutes of Health. Such underestimation of HTLV-1 by health agencies has led to a remarkable lack of funding supporting research and development of treatments and vaccines, causing HTLV-1 to remain a global threat. Nonetheless, there are emerging novel therapeutic and prevention strategies which will help people who have diseases caused by HTLV-1. In this review, we present a brief historic overview of the key events in HTLV-1 research, including its pivotal role in generating ideas of a retrovirus cause of AIDS and in several essential technologies applicable to the discovery of HIV and the unraveling of its genes and their function. This is followed by the status of HTLV-1 research and the preventive and therapeutic developments of today. We also discuss pending issues and remaining challenges to enable the eradication of HTLV-1 in the future.

Keywords

Human T-cell leukemia virus-1, human oncovirus, human retrovirus, adult T-cell leukemia, HAM/TSP, Central Australia, STD, vaccine

Open Peer Review

Approval Status

	1	2
version 1
28 Feb 2019		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Anne Van den Broeke**, Experimental Hematology, Institut Jules Bordet, Brussels, Belgium
 Université de Liège (ULiège), Liège, Belgium
2. **Roberto S Accolla**, University of Insubria, Varese, Italy

Any comments on the article can be found at the end of the article.

Corresponding author: Yutaka Tagaya (ytagaya@ihv.umaryland.edu)

Author roles: **Tagaya Y:** Conceptualization, Data Curation, Investigation, Project Administration, Resources, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Matsuoka M:** Conceptualization, Data Curation, Investigation, Resources, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Gallo R:** Conceptualization, Resources, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Tagaya Y *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Tagaya Y, Matsuoka M and Gallo R. **40 years of the human T-cell leukemia virus: past, present, and future [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):228 <https://doi.org/10.12688/f1000research.17479.1>

First published: 28 Feb 2019, 8(F1000 Faculty Rev):228 <https://doi.org/10.12688/f1000research.17479.1>

The discovery of HTLV-1

It has been 40 years since human T-cell leukemia virus (HTLV)-1¹ was discovered by the Gallo group at the National Cancer Institute/National Institutes of Health (NCI/NIH) as the first human retrovirus. Thus, it is fitting to start this review by looking back at the chronology preceding the discovery of HTLV-1. The group, focusing on virology, has been pursuing the biochemical purification and characterization of the reverse transcriptase since the early '70s. In the mid-'70s, they identified the first T-cell growth-promoting cytokine², now known as interleukin-2 (IL-2), in their efforts to enable a long-term culture of human T cells so they could study cells isolated from patients with leukemia. All of these efforts paved the way for the group to discover a new retrovirus from human T cells, the HTLV-1; subsequently, the same group discovered the second human retrovirus (HTLV-2)³ and co-discovered the third human retrovirus, now known as HIV-1 as the cause of AIDS⁴. In 1981, at a conference held in Kyoto (near Lake Biwa), the Gallo group reported that sera from patients with adult T-cell leukemia (ATL), described below, contain antibodies against the purified p24 protein of the HTLV⁵. Later that year, a Japanese group led by Hinuma isolated a similar type C-retrovirus from an ATL cell line and also showed that sera from patients with ATL contain antibodies reactive with cells infected with the new virus⁶. This virus was later shown to be identical to HTLV-1^{7,8}.

Impact of HTLV-1 on the discovery of HIV

HTLV-1 was the first human retrovirus discovered⁹. It shifted the paradigm in the virology world in many ways by demonstrating not only that retroviruses can infect humans but also that retroviruses can be pathogenic in humans. In 1982, the Gallo group reported the second human retrovirus, HTLV-2¹⁰. Around the same time, reports of a rare form of lung infection, *Pneumocystis carinii* pneumonia, among homosexual young men started to appear from the west-coast areas of the US and soon from other parts of the world, which the US Centers for Disease Control and Prevention named "acquired immunodeficiency syndrome" (AIDS). It drew the attention of virologists, and in 1982 Max Essex and Gallo postulated that a new type of (retro)virus may be associated with AIDS, although the scientific community remained skeptical. In 1983, the Montagnier group at the Pasteur Institute in Paris reported the discovery of a new retrovirus (lymphadenopathy virus, or LAV) from one patient with AIDS¹¹. In 1983 and 1984, the Gallo group reported the isolation of a human retrovirus (HTLV-III) in 48 patients with AIDS and, along with their blood test, linked the virus to AIDS as the cause^{4,12–18}. LAV and HTLV-III were shown to be the same virus^{19–22}, and the name HIV (human immunodeficiency virus) was adopted in 1986. The technological approach was the same as for the HTLVs. Studies on HTLVs also provided both conceptual and scientific methodology critical to the discovery of HIV²³; thus, the discovery of HTLV-1 and -2 laid the foundation for the discovery of HIV. Moreover, it provided the framework by creating the "human retrovirology field". Furthermore, the study on the *pX/Tax* gene of HTLV-1 accelerated the mechanistic understanding of the action of HIV through the study of regulatory elements of this virus^{24–26} (for example, *Tat*²⁷ and *Rev*²⁸), as *Tax* served as the prototypic example of human

retroviral regulatory genes. HIV and HTLV can co-inhabit, as the first isolate of HTLV-III from the Gallo group came from a person who was doubly infected by HTLV-1 and HIV, most likely through blood transfusion, and the same T cells from this individual were producing HTLV-1 and HIV, which challenged the strongly held view at that time of "viral interference", stating that a cell infected by a retrovirus resists superinfection by another retrovirus. This prevented the Gallo group from announcing the discovery of HTLV-III (HIV) for several months because of the confusion it caused to the group before they realized that these cultures contained HTLV-1 plus a new retrovirus (HIV). On the other hand, this established a new methodology of stably maintaining HIV in culture because CD4 T cells doubly infected by HTLV-1 and HIV would remain viable and keep producing HIV whereas an infection by HIV alone would kill the target CD4 T cells. This led to the concept that immortalized (transformed) CD4 T cells could continuously produce HIV. By adopting HIV to mature CD4 T cells already transformed by other causes than HTLV-1, the cells maintain their growth and enabled the mass production of HIV (as early as 1983), which was essential for establishing a global blood test for HIV⁴ and central for the testing of anti-HIV drugs.

Exceptional oncogenicity of HTLV-1

HTLV-1 was the first retrovirus identified from humans. Moreover, it is one of the first human viruses which were proven to have oncogenic effects in humans, together with Epstein-Barr virus (EBV) (also known as human herpesvirus-4)^{29,30} and papilloma viruses^{31,32}. Although the oncogenic capability of papilloma viruses is as solid as that of HTLV-1, the extent to which EBV/HHV-4 directly causes malignancy is still in dispute^{30,33}. Despite the prolific nature of EBV/HHV-4 reaching 90% prevalence among adult humans, the associated malignancies such as Burkitt's lymphoma (BL), Hodgkin's lymphoma and nasopharyngeal carcinoma are yet unconventional. In addition, BL can occur in the absence of EBV/HHV-4³⁰. EBV/HHV-4 is the most powerful B-cell transforming factor *in vitro*³⁰. However, the pattern and regulation of EBV gene expression are strikingly different between *in vitro* transformed cells and *in vivo* BL cells³⁴. It is unquestionably a triggering factor for human malignancy, but EBV/HHV-4 appears to require co-factors to cause cancers³⁰.

HTLV-1 manifests many diseases, including ATL, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), inflammatory disorders, especially uveitis, arthritis, and dermatitis, and an immune-deficient state, resulting in bronchiectasis that is causing high mortality in Central Northern Australia³⁵. (This topic will be elaborated on below, see also [Table 1](#)).

The major manifestation is the T-cell leukemia (ATL), and the lifetime risk of HTLV-1-infected people to develop ATL is estimated to be around 5%. However, a recent publication³⁶ from Taylor's group suggests an intriguing re-estimation. Most ATL cases develop from those who contracted HTLV-1 at birth, through mother-to-child infection, but ATL is rarely seen in HTLV-1 carriers who have been infected in adulthood. This is an interesting contrast with the myelopathy HAM/TSP, the second

Table 1. List of human T-cell leukemia virus-1 (HTLV-1) diseases. HBZ, HTLV-1 bZIP factor.

Disorders	Disease manifestation	Prognosis, prevalence	Remarks	Therapy
Leukemia/Lymphoma	CD4 T-cell leukemia (adult T-cell leukemia, ATL)	Fatal leukemia with 4 subtypes Occurs in 3~5% of all carriers, in 20% after infection around birthtime	Develops after 3~5 decades of latency period.	No standard therapy
Myelopathy	HTLV-1 associated Myelopathy/Spastic paraparesis, HAM/TSP.	Progressive, resembles multiple sclerosis Occurs in 0.3~5% of all carriers. More prevalent and rapidly progressive with infections associated with transplants.	Develops after 2~4 decades of latency period.	No standard therapy
Immunodeficiency	T-cell immunodeficiency Bronchiectasis	Seen even in asymptomatic carriers. Causing high morbidity/mortality among Australian indigenous people	More often seen with HTLV-1 subtype c (Melanesia)	No standard therapy
Inflammatory	Uveitis, arthropathy, dermatitis, exocrinopathy, myositis		Caused by HBZ?	

major HTLV-1 disease, which is seen with higher prevalence and accelerated disease progression in those who were infected by HTLV-1 in adulthood because of a blood transfusion or organ-transplantation involving infected T-lymphocytes than those who were infected in the perinatal period. It is also known that perinatal infection accounts for about 20 to 25% of all HTLV-1 infections. Thus, the Taylor group estimates that the true risk of ATL among perinatally infected carriers could be as high as 25%³⁶, a striking number outweighing even the risk of lung cancer associated with tobacco smoking (around 16%³⁷). Earlier, we reported that HTLV-1 displays higher carcinogenic potential than that of any known human oncovirus. This new study suggests that HTLV-1 is arguably one of the most carcinogenic agents known to humans (but thankfully it is not easily transmitted from person to person). Another unique oncogenic nature of HTLV-1 is that it is a direct mechanism (see below for details). Because of the outstanding transforming capability of HTLV-1, we recently returned to its original name (human T-cell leukemia virus-1) and away from human T-lymphotropic virus-1. This was supported by a large majority vote at the 2017 HTLV-1 international meeting in Tokyo³⁸. (We are often asked whether an official committee needs to approve the naming of a virus. The only international committee in virology—the International Committee on Taxonomy of Viruses—clearly states on its home page that they deal only with taxonomy and that the name of individual viruses will be determined by a peer-reviewed publication. Thus, the recent renaming of the HTLV-1 to “leukemia virus” is legitimate and hopefully final.)

Epidemiology of HTLV-1

The discovery of ATL³⁹ predates that of HTLV-1¹. The geographical distribution of patients with ATL, in Japan and in other parts of the world (for example, the Caribbean basin), prompted researchers to hypothesize that an infectious microorganism causes the disease. As shown in [Figure 1](#) (kindly permitted by the

authors⁴⁰ and the publisher for adoption here), HTLV-1 shows a unique endemic distribution on a global scale, involving Japan, the Caribbean islands, South America (Brazil, Colombia, Chile, and Peru), West and Central Africa, Romania, parts of the Middle East (especially Iran), and Central Australia. As discussed below, HTLV-1 is unusually inactive in replication as a virus and rather exists as a genetic element in infected cells after integration. This behavior of HTLV-1 has been used for anthropology studies as well⁴¹ to track historical migration of humans. For example, the high prevalence of Asian type HTLV-1 in Japan and among the indigenous people of North and South America suggests that the migration of HTLV-1 (subtype B) infected humans from Asia to America when these two parts were connected through land bridge during the last ice age almost 10,000 years ago. The map, however, also suggests that global epidemiology studies are still to be completed. For example, some heavily populated areas such as India, China, much of Russia, and Sub-Saharan Africa do not offer detailed epidemiologic information on HTLV-1 infection. The strange lack of appropriate funding for such studies is a common obstacle on a global scale for HTLV research.

HTLV-1 can be transmitted from carrier mother to the baby mainly through breast feeding. Equally important is the horizontal transmission by sex and transfer of infected lymphocytes, such as blood transfusion and organ transplant. It is important to emphasize that HTLV-1 infection requires absolute cell-to-cell contact⁴² but that cell-free virions generally do not cause infection. Shortly after the discovery of HTLV-1, many countries adopted HTLV-1 screening in donated blood, effectively reducing the risk of HTLV-1 transmission by transfusion. However, such screening is not yet performed all over the world. Moreover, only few countries (the UK and France) perform HTLV-1 screening on individuals who donated organs. The US has dropped similar screening because of the concerns over losing intact organ sources⁴³ and the argument that HTLV-1 infection

Figure 1. Global distribution of endemic foci of HTLV-1 infection. The figure represents an estimated number of HTLV-1–infected individuals, based on reliable epidemiological data from studies targeting pregnant women, blood donors, or different adult populations or a combination of these. It is noteworthy that, even within a given country, the endemic foci are not evenly distributed. Some of the “empty” areas represent those in which detailed epidemiological studies have never been conducted (for example, India and China). HTLV-1, human T-cell leukemia virus-1. Adapted from Gessain and Cassar⁴⁰ with their kind permission.

in adulthood should not be a medical threat because the prevalence of ATL is low and requires a latency period of four to five decades (<https://optn.transplant.hrsa.gov/resources/guidance/guidance-for-htlv-1-screening-and-confirmation-in-potential-donors-and-reporting-potential-htlv-1-infection/>). Recent studies in Japan, however, provide a different view on this. Yamano and co-workers have studied the post-transplantation development of HAM/TSP by infected organs, which suggests that the myelopathy occurs at about 20 times higher risk (nearly 10% of post-transplantation over 0.3% of mother-to-child transmission). Additionally, the disease rapidly progresses to morbidity within 5 years of infection, which is a striking contrast to the two to three decades of delayed onset and additional two decades of disease development for reaching the final stage of HAM after perinatal infection. This new study (<https://www.mhlw.go.jp/file/04-Houdouhappyou-10905500-Kenkoukyoku-Zoukiishokushitsu/0000068136.pdf>) may be a serious alert to the global medical community to review and revise their policy on HTLV-1's threat as a blood-borne pathogen.

An emerging issue: endemic in Central Australia

One of the most recent additions to the HTLV-1 epidemiology is Central Australia. Early in the '90s, HTLV-1 infection in Melanesia was observed. Furthermore, Melanesian HTLV-1 is genetically divergent from major subtypes found in other parts of the world⁴⁴ (cosmopolitan subtype A seen in Japan, the Caribbean, Central and South America, the Middle East, and North and South Africa and the Central African subtype B) and hence named subtype C. Like subtype A and B, subtype C appears to have evolved from simian T-cell leukemia viruses (STLVs) (the ancestral viruses to HTLV-1/2), but intriguingly genetic analysis suggests that the

evolution of subtype C might have been independent of other subtypes⁴⁵. Recent studies revealed that the divergence is highest in a part of the *pX* region near the 3' end of the virus. This region encodes for small HTLV-1 proteins such as p30, p12, p13, and p8 that have been extensively studied by the Franchini group (NCI), which showed that these proteins expressed from the open reading frame (ORF) I or II display diverse regulatory functions⁴⁶. How this would affect the pathogenesis of subtype C is still under investigation.

The profound impact of HTLV-1 on the indigenous people of Australia was not recognized until recently, which is another testimony that our understanding of global HTLV-1 infection is still incomplete. Einsiedel *et al.* demonstrated that some communities of Aboriginal people showed 45% HTLV-1 sero-positivity⁴⁷. The Central Australian HTLV-1 infection presents two emerging issues for the HTLV-1 community. One is the opportunity to study differences of new subtype C and other subtypes and connect them to its pathogenicity. As described below, HTLV-1 subtype C may be distinct from major subtypes in terms of the diseases it causes. In addition, as discussed below, it is a challenge because solving this issue requires not just biological research and medical treatment but social support as well. Again, the threat of HTLV-1 to humankind has been severely underestimated. So it is good news that the Australian government has announced new funding to address the issue.

Pathogenic mechanism of HTLV-1 diseases

The disease concept of ATL was established in the mid-'70s by Takatsuki and co-workers^{39,48} before HTLV-1 was discovered; then another HTLV-1 disease was identified around 1985. A

unique myelopathy called TSP was described in the Caribbean area⁴⁹. Gessain and de Thé demonstrated that HTLV-1 infection is associated with this neuronal disease⁵⁰. In 1986, Osame *et al.* showed that HTLV-1-infected individuals develop a unique myelopathy (HAM)⁵¹. The two diseases are identical and hence the name HAM/TSP was adopted. Later studies show that HTLV-1 is also associated with inflammatory diseases^{52,53} other than the two diseases already mentioned, such as uveitis^{54,55}, arthropathy, pneumopathy, dermatitis, exocrinopathy, and myositis. Furthermore, HTLV-1 may cause immunodeficiency. Clinicians earlier observed that ATL is often associated with immunodeficiency which may cause opportunistic infections, but even asymptomatic carriers (ASCs) have mild immunodeficiency (K. Takatsuki, personal communication). This is being revisited from a new perspective in light of the recent finding that infection of HTLV-1 subtype C among Australian indigenous people is causing high morbidity/mortality by triggering chronic lung infections, including bronchitis, bronchiolitis, and bronchiectasis⁵⁶.

Globally, ATL is the major manifestation of HTLV-1. ATL is now categorized into four types: chronic⁵⁷, smoldering⁵⁸, acute⁴⁸, and lymphoma⁵⁹ (reviewed by Takatsuki⁶⁰). The direct causative role of HTLV-1 for this leukemia is solid. Shortly after the discovery of the virus, the *in vitro* transforming ability of this virus was reported⁶¹. The transforming ability of HTLV-1 was subsequently mapped to a region between the *pol* and 3' long terminal repeat (LTR), named the *pX* region, and a non-canonical oncogenic component was identified and named Tax-1. Tax-1 does not show sequence homology to any mammalian gene including known oncogenes. Tax-1 strongly activates the transcription of many host genes^{62–64} in addition to HTLV-1's 5'LTR⁶⁵. Soon, it was shown that the transcriptional activation by Tax-1 is mediated by nuclear factors, including nuclear factor kappa B (NFκB)^{66,67}. Subsequent studies depicted how Tax-1 activates the NFκB pathway⁶⁸. Tax binds to IKKγ (inhibitor of NFκB kinase gamma) and activates the IKKα/β/γ complex^{69–71}, which facilitates the nuclear translocation of p50/p60 of NFκB. Tax also enhances the processing of NFκB p100 into the active p52 form and thereby activates the “non-canonical” NFκB pathway⁶⁸. Alternatively, TaxBP1, a cellular binding protein to Tax which functions as an autophagy receptor, is known to repress TRAF-6 (TNF receptor-associated factor-6)/NFκB signaling. Tax can restore NFκB signaling by binding to TaxBP1 and modulating its function.

To validate the transforming role of Tax *in vivo*, Tax transgenic mice were generated. Using the 5' LTR of HTLV-1 as enhancer/promoter, Tax expression caused mesenchymal tumors in mice⁷². Another study demonstrated that Tax transformation is mediated by the downstream activation of NFκB⁷³. More recently, Bazarbachi and co-workers showed that Tax transforms *Drosophila* eye cells⁷⁴ and Cheng *et al.* showed that Tax immortalizes human dendritic cells *ex vivo*⁷⁵. Thus, Tax has broad transforming effects in a variety of cells across species. However, the development of T-cell malignancy by Tax requires the T cell-specific expression of this gene (Hasegawa and Hall *et al.*⁷⁶). A small caveat of this study was that the malignant cells do not express CD4 or CD8; thus, they resemble pre-T cell

leukemia/lymphoma whereas *in vivo* ATL cells show a mature regulatory T (Treg)-like phenotype, although expression of CD4 may not be found in all tumor cells of patients with ATL⁷⁷. These studies show that Tax is oncogenic but does not determine cell specificity of ATL.

However, a completely independent scenario was presented through studies conducted recently. In 2002, Gaudray and Mesnard *et al.* discovered that HTLV-1's minus strand contains a reading frame which encodes a potential transcription factor named HBZ (HTLV-1 bZIP factor)⁷⁸. Subsequent studies by a group led by one of the authors (MM) demonstrated that HBZ is a very complex gene with many intriguing facets^{79–83}. It appears to function not only as a protein but also as a regulatory RNA which promotes proliferation of host cells⁸⁴. As a protein, HBZ activates the transforming growth factor beta (TGF-β)/Smad pathway, which leads to transcriptional activation of the *Foxp3* gene⁸⁵. This finding explains why *in vivo* ATL leukemic cells are Foxp3-positive and HTLV-1-infected cells in ASCs and patients with HAM/TSP are within the Foxp3⁺ subpopulation of CD4 T cells (Figure 2). It is noteworthy that there is no evidence that Tregs are the only exclusive target of HTLV-1 infection⁸⁶. Instead, HTLV-1 orchestrates the T-cell molecular program to transform conventional T cells to look like Tregs^{87,88}. Another important message is that the inflammatory responses seen with HTLV-1 infections can be caused by HBZ⁸⁹, in part by the production of various pro-inflammatory cytokines, including TGF-β⁸⁵ and interferon gamma (IFNγ)⁹⁰, by infected CD4 T cells and non-infected blood cells. Additionally, HBZ inhibits canonical NFκB and Wnt pathways⁹¹. HBZ also induces expression of CCR4 and TIGIT at the cell surface^{92,93}. Importantly, CCR4 is implicated not only in migration but also in the proliferation of T cells⁹⁴. Likewise, the upregulation of TIGIT, a co-inhibitory molecule, may help evade anti-ATL/HTLV-1 immunity and facilitate the propagation of ATL leukemic cells⁹². Finally, evidence that HBZ can also cause CD4 T-cell malignancy was provided when this gene was expressed as a transgene in mouse T cells⁸⁷. Curiously, malignant T cells in HBZ transgenic mice express markers (for example, CD25 and CCR4) which are commonly seen with *in vivo* ATL cells. So what is the indispensable transforming component of HTLV-1? At the moment, this remains an open question. Earlier studies revealed that HTLV-1 is quite often (>40%) integrated as a defective provirus which still later helps in the development of ATL⁹⁵. In many cases, the deletion involves the 5' LTR and cripples the capacity of the virus to express components in the positive strand including Tax. Such defective viruses are much more commonly seen among patients with ATL than in ASCs⁹⁶. Curiously, no deletion of 3' LTR was found, suggesting the critical need for HTLV-1 to retain an antisense-encoded gene (or genes). Also, recent analyses using the next-generation sequencing technology demonstrate that the majority of the HTLV-1 transcripts in *in vivo* leukemic cells are driven by the 3'LTR, but not by the 5'LTR (see below for more). Antisense genes appear to be a common and critical element of retroviridae. Bovine leukemia virus (BLV), HTLV-1's sibling virus in cows, also expresses antisense transcripts which are expressed in bovine tumors and associated with cellular transformation⁹⁷. HIV-1 also encodes an antisense gene and uses it to mediate critical functions for the virus⁹⁸. So we ask the question again,

Figure 2. Inflammatory phenotype of HTLV-1-infected cells triggered by HBZ. Target cells of HTLV-1 are effector/memory T cells and Foxp3⁺ T cells *in vivo*. HBZ promotes the transcription of the *Foxp3* gene by enhancing transforming growth factor-beta (TGF- β)/Smad signaling, which leads to the peripheral increase of induced Tregs (iTregs) and Foxp3⁺ T cells. However, note that Foxp3 expression is unstable in these cells. When Foxp3 expression is lost, “exFoxp3” cells produce IFN γ , which causes inflammation and promotes leukemogenesis. HBZ, human T-cell leukemia virus-1 bZIP factor; HTLV-1, human T-cell leukemia virus-1; IFN γ , interferon gamma; Treg, regulatory T.

Tax or HBZ? Curiously, HTLV-1's sister virus HTLV-2 shows no oncogenic capability, although HTLV-2 also encodes a *Tax* gene (*Tax-2*), which is a potent transforming gene *in vitro*⁹⁹. Whereas *Tax-1* and -2 are highly conserved (>89% identity)¹⁷, the antisense genes (HBZ and APH-2 of HTLV-2) are very divergent. The Green lab has shown that APH-2 of HTLV-2 functions as a regulatory factor in host cells^{100,101} and is functionally very different from HBZ. These results favor HBZ as the dominant factor in the leukemic transformation. However, the activation of NF κ B, which has been considered an essential part of HTLV-1-related cellular transformation, is only caused by Tax, but not by HBZ⁹³, which is seen as a caveat of “the HBZ hypothesis”. Two recent studies indicate that Tax expression *in vivo* is transient and seen as only a burst during the cell cycle^{102,103}. The pulsive expression of Tax, however brief, facilitates the survival of HTLV-1-infected cells by minimizing the alert to the host immune surveillance mechanism¹⁰³ since the Tax protein *per se* is strongly immunogenic^{104,105}. Moreover, host restriction factors play a role in silencing the function of Tax and viral replication^{106–108} and conceals the role Tax might have played in the early phase of cellular transformation. Similar to many other cancer cells, HTLV-1-inserted/transformed cells accumulate somatic mutations. The advancement of next-generation sequencing technology has accelerated the research addressing host genomic alterations caused by HTLV-1. An integrated molecular analysis¹⁰⁹ (genome, exome, transcriptome, methylation, and so on) highlighted that alterations were frequently found in Tax-interactome and T-cell activation pathways, including NF κ B signaling, trafficking, and immunosurveillance pathways. Gain-of-function mutations were also seen in association with various T-cell signaling molecules, observations that are consistent with previous consensus on the importance of the Tax-NF κ B axis in the cellular transformation by HTLV-1.

Curiously, this study also recapitulated the above-mentioned reports^{95,96} that integrated HTLV-1 proviral genome often displays deletions in the 5' viral segments, resulting in defective viral replication and production. Moreover, viral transcripts are produced predominantly from the antisense strand, consistent with the importance of HBZ in the development and maintenance of established ATL cells. It is also of note that most antisense transcripts extend beyond the 5' LTR of HTLV-1 and include neighboring host genes juxtaposed to the integration site¹⁰⁹, suggesting the novel role for 3' LTR as the driver of HTLV-1-related transcriptome. It has been held that the integration of HTLV-1 into the host genome is random. However, new studies challenge this paradigm^{110,111}. Most recently, Rosewick and van den Broeke *et al.* showed that integration of HTLV-1 and BLV preferentially occurs near cancer drivers and that insertional mutagenesis appears to drive the clonal persistence and expansion of transformed T cells¹¹². All of these findings were supported by another recent publication¹¹³. In addition, Satou and Bangham *et al.*¹¹⁴ demonstrated that HTLV-1 has a binding site for CTCF, a regulator of chromatin structure. They showed evidence that the insertion of HTLV-1 creates a novel loop structure between the provirus and host genome by recruiting CTCF, which naturally alters the expression of proviral and host genes. Collectively, the characterization of HTLV-1 integration and its impact on the host transcriptional and epigenetic regulations constitute an emerging research field, as is the role of Tax and HBZ for cellular transformation. Even the once-accepted paradigm of the necessity of NF κ B activation, may need to be further investigated in light of these new findings.

Whereas the oncogenic process of ATL appears mainly molecular and virologic, the pathogenesis of HAM/TSP is more immunologic¹¹⁵. In HAM/TSP, the major symptoms appear to

be caused by the damages to spinal neuronal cells by inflammatory T cells. The suggested mechanism includes the acquisition of an inflammatory nature by HTLV-1-infected CD4 T cells and non-leukemic CD8 T cells. As discussed earlier, HBZ of HTLV-1 facilitates the generation of inflammatory CD4 T cells^{85,89,91}. Possibly relevant to the pathogenesis of HAM/TSP is the recent observation that the HBZ protein localizes exclusively in the cytoplasm of lymphocytes in patients with HAM/TSP¹¹⁶, as opposed to the predominant nuclear localization of HBZ in leukemic cells in patients with ATL, suggesting the presence of a HAM/TSP specific use of HBZ in the development of the disease. In addition to cytokines, chemokines CXCL-9 and -10 are produced by HTLV-1-infected CD4 T cells and play important roles in recruiting inflammatory T cells to the site of neuronal destruction¹¹⁷. Furthermore, Azimi, Jacobson, and Waldmann have suggested that γ c-cytokines, in particular IL-2 and IL-15, are produced by HTLV-1-infected CD4 T cells via the transcriptional trans-activation by Tax and in turn activate CD8 T cells into inflammatory T cells^{118–121} which produce tissue-damaging cytokines such as IFN γ . These molecules are attractive therapeutic targets in treating HAM/TSP, as discussed below.

Therapy development for HTLV-1 diseases

As mentioned earlier, the prognosis for HTLV-1 diseases is still poor despite almost 40 years of studies on mechanisms and efforts to develop therapeutic strategies. The acute/lymphomatous ATL is very resistant to conventional chemo/radiation therapy. Thus, surface markers specific for HTLV-1-infected CD4 T cells were sought after to enable targeting. The first marker was IL-2R α /CD25¹²² (then called the Tac antigen¹²³). Anti-IL-2R α /Tac therapy, including the conjugation of the antibody to toxins or α / β -emitters, has been tried with some success^{124–127}, but resistant leukemic clones quickly emerged. More recently, CCR4, a chemokine receptor, was identified as an ATL-specific marker^{94,128–132} and anti-CCR4 therapy (using a defucosylated anti-CCR4 antibody) has been clinically tested in Japan with promising results^{129,133–136}. The only caveat was that anti-CCR4Ab (mogamulizumab) also depleted natural regulatory T cells (nTregs) and caused hyper-autoimmunity (Stevens–Johnson syndrome) in some cases, which led to one fatal case in the treatment¹³⁷. Nevertheless, it has been approved as an anti-ATL drug in Japan and clinical trials are being performed in the US as well. Arsenic trioxide, which has been used for AML treatment, was also shown to have anti-ATL effects^{138,139} and showed therapeutic effects on chronic ATL cases¹⁴⁰, and there is suggestive evidence that this treatment might eradicate “leukemia-initiating cells”¹⁴¹. Also, anti-viral drugs have been tested. Previous findings suggest that HTLV-1 does not actively replicate in CD4 T cells in carriers and patients, prompting the field to consider that anti-viral therapy is not an option in treating HTLV-1 diseases. However, recent research presents more diversified views on this topic^{142–146} as anti-viral treatments show some promising results in clinical trials. Collectively, it is fair to say that promising treatments are developing for ATL, but additional strategies should be encouraged as well, including T cell-mediated immunotherapies targeting HTLV-1 components. Historically, it has been repeatedly shown that Tax of HTLV-1 is highly immunogenic and that

HTLV-1-infected individuals have anti-Tax Ab and anti-Tax T cells in their circulation, which prompted the field to explore anti-Tax strategies. However, Asquith and Bangham *et al.*¹⁴⁷ investigated which epitope of HTLV-1 would elicit T-cell immunity leading to decreased proviral load of HTLV-1. Surprisingly, it was not anti-Tax or anti-Env but anti-HBZ immune responses which correlated with protective effects¹⁴⁷. Additional work by Sugata and Matsuoka *et al.* appears to solidify this possibility¹⁴⁸ and offers a promising new venue for the future. As in many other leukemias, bone marrow transplantation (BMT) is being used. Curiously, attempts of autologous BMT were unsuccessful¹⁴⁹. In contrast, allogeneic BMT resulted in complete remission in some cases, and it has been suggested that the extent of graft-versus-host response correlates with a favorable outcome¹⁵⁰. Immune cells in patients with ATL may be tolerized against HTLV-1, most likely because their immune system has developed in the presence of HTLV-1.

Compared with the pathogenesis of ATL, the pathogenesis of HAM/TSP is more complicated as the damage of spinal cord neuronal cells, the core event causing myelopathy, is mediated by inflammatory responses involving CD8 T cells triggered by HTLV-1-infected CD4 T cells in a bystander manner¹⁵¹. So strategies targeting both CD4 and CD8 could be pursued. Here again, anti-CCR4 therapy, which should help eliminate HTLV-1-infected CD4 T cells¹⁵², was recently tried with intriguing results in a clinical trial in Japan¹⁵³. First, the treatment showed quick improvements of clinical symptoms, prompting the field that the presumed low replication of HTLV-1 *in vivo* may need reinvestigation. Anti-CCR4 strategy was among the first to show therapeutic efficacy, so the completion of the clinical trial, including the monitoring of long-term effects, is keenly awaited. As mentioned above, CD8 T cells play as important a role as CD4 T cells in HAM/TSP, so the CD8 targeted therapy can be pursued as well. Studies from NIH labs (Waldmann and Jacobson) demonstrated that one unique characteristic of T cells from patients with HAM/TSP is that they grow *ex vivo* without any exogenous stimulation (for example, antigen or cytokine), which they named spontaneous proliferation¹¹⁸, which presumably reflects the constitutive activation of T cells in patients with HAM/TSP. This is because HTLV-1 infection causes CD4 T cells to produce T-cell growth factors such as IL-2 and IL-15^{118,120,121,154,155}. Thus, inhibition of these cytokines by antibodies¹²¹, Jak inhibitors¹⁵⁶, or newly described multi-cytokine inhibitory peptide (BNZ132-1 or BNZ-1^{154,155}) synthesized by one of the authors (YT) can subside the T-cell activation in patients with HAM/TSP and is a viable option for treating HAM/TSP for which no established therapy is yet available. In summary, recent years have seen more promising developments for HTLV-1 diseases. The time has come for more testing of novel ideas to cure or reduce morbidity from these diseases.

Prevention and eradication of HTLV-1: the need for a global coordination of HTLV-1 research and its implementation

As mentioned above, HTLV-1 is among the most carcinogenic agents known to humans and has the additional burden of causing other diseases. Yet owing to its extremely weak

dissemination and to its ancient infection of humans (giving time for humans to adapt), HTLV-1 is not considered to be as much of a global threat as other viruses. However, we have seen an instantaneous burst of virulence with other viruses due to mutations (for example, influenza virus, Ebola, and HIV), so we should not be so sure. Moreover, in several parts of the world, it is not as uncommon as previously noted. The modes of HTLV-1 transmission and replication suggest that the infection is preventable. Recently, we wrote an open letter to the World Health Organization (WHO), urging them to pay due awareness for HTLV-1, as we strongly feel that HTLV-1's threat is vastly under-recognized¹⁵⁷; for example, it was not on the WHO's list of sexually transmitted diseases, and remarkably in recent years under Director Harold Varmus (who was a chicken retrovirologist and molecular biologist), the NCI did not even have it on the list of human tumor viruses. We argued that the mother-to-child transmission can be controlled by screening and educating HTLV-1 carrier pregnant women. Three decades ago, a prefecture in Japan (Nagasaki) started such an endeavor, which reduced the HTLV-1 prevalence in the area from 7.2 to 1.4%¹⁵⁸. It is now adopted by the Japanese government into a nationwide anti-HTLV-1 strategy. The horizontal transmission of HTLV-1, by sex and transfer of infected blood cells, is equally preventable. To this end, some countries have initiated HTLV-1 screening in donated blood in the late '80s. However, blood screening is not yet implemented in any nation in Africa, one of the most highly endemic regions of HTLV-1 infection. An additional emerging concern is the HTLV-1 infection upon organ transplantation which may cause increased development of HAM/TSP with rapid progression (described above). As of now, very few nations (only France and the UK) are conducting HTLV-1 screening in donated organs. Attempts to create funding to facilitate the screening as well as invention

of new technologies to make such screening easier and attainable are still needed.

What about a vaccine? From the late '80s to early '90s, several groups came out with an HTLV-1 (and STLV) vaccination plan, which was effective but only partially so^{159–161}. However, our knowledge of HTLV-1 biology, together with the maturation of the vaccination field in general, has vastly advanced since then. The Franchini group (NCI) has used more efficient adjuvants, and the vaccine was proven effective in macaques¹⁶². Recent studies suggest that targeting HBZ, a new strategy, may be more effective than conventional strategies^{147,148,163}. However, development of anti-HTLV-1 therapeutic/preventive vaccination is severely hampered by the lack of funding for clinical trials.

As the conclusion of this review, we argue, on behalf of the global HTLV-1 community, that efforts toward the eradication of HTLV-1 constitute a global health need. At the ninth annual meeting of the Global Virus Network in Melbourne, Australia in September 2017, we met representatives of the Aboriginal community who pleaded to be rescued from their sufferings from HTLV-1. We urge medical/health agencies all over the world that the threat of HTLV-1 is real and there are still unmet medical needs to be resolved and much more awareness is needed. Finally, progress in developing a vaccine for HTLV-1 should be easier than HIV because it has less variation, and may provide important lessons for HIV.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Poiesz BJ, Ruscetti FW, Gazdar AF, *et al.*: **Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.** *Proc Natl Acad Sci U S A.* 1980; **77**(12): 7415–9. [PubMed Abstract](#) | [Free Full Text](#)
- Morgan DA, Ruscetti FW, Gallo R: **Selective *in vitro* growth of T lymphocytes from normal human bone marrows.** *Science.* 1976; **193**(4257): 1007–8. [PubMed Abstract](#) | [Publisher Full Text](#)
- Poiesz BJ, Ruscetti FW, Reitz MS, *et al.*: **Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia.** *Nature.* 1981; **294**(5838): 268–71. [PubMed Abstract](#) | [Publisher Full Text](#)
- Popovic M, Sarngadharan MG, Read E, *et al.*: **Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.** *Science.* 1984; **224**(4648): 497–500. [PubMed Abstract](#) | [Publisher Full Text](#)
- Gallo RC: **Kyoto Workshop on some specific recent advances in human tumor virology.** *Cancer Res.* 1981; **41**(11 Pt 1): 4738–9. [PubMed Abstract](#)
- Hinuma Y, Nagata K, Hanaoka M, *et al.*: **Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.** *Proc Natl Acad Sci U S A.* 1981; **78**(10): 6476–80. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Popovic M, Reitz MS Jr, Sarngadharan MG, *et al.*: **The virus of Japanese adult T-cell leukaemia is a member of the human T-cell leukaemia virus group.** *Nature.* 1982; **300**(5887): 63–6. [PubMed Abstract](#) | [Publisher Full Text](#)
- Watanabe T, Seiki M, Yoshida M: **HTLV type I (U. S. isolate) and ATL (Japanese isolate) are the same species of human retrovirus.** *Virology.* 1984; **133**(1): 238–41. [PubMed Abstract](#) | [Publisher Full Text](#)
- Poiesz BJ, Ruscetti FW, Mier JW, *et al.*: **T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor.** *Proc Natl Acad Sci U S A.* 1980; **77**(11): 6815–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, *et al.*: **A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia.** *Science.* 1982; **218**(4572): 571–3. [PubMed Abstract](#) | [Publisher Full Text](#)
- Barré-Sinoussi F, Chermann JC, Rey F, *et al.*: **Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).** *Science.* 1983; **220**(4599): 868–71. [PubMed Abstract](#) | [Publisher Full Text](#)
- Arya SK, Gallo RC, Hahn BH, *et al.*: **Homology of genome of AIDS-associated virus with genomes of human T-cell leukemia viruses.** *Science.* 1984; **225**(4665): 927–30. [PubMed Abstract](#) | [Publisher Full Text](#)
- Gallo RC, Salahuddin SZ, Popovic M, *et al.*: **Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.** *Science.* 1984; **224**(4648): 500–3. [PubMed Abstract](#) | [Publisher Full Text](#)
- Safai B, Sarngadharan MG, Groopman JE, *et al.*: **Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency**

- syndrome. *Lancet*. 1984; 1(8392): 1438–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Samgadharan MG, Popovic M, Bruch L, *et al.*: Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. *Science*. 1984; 224(4648): 506–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Schüpbach J, Popovic M, Gilden RV, *et al.*: Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. *Science*. 1984; 224(4648): 503–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Shaw GM, Gonda MA, Flickinger GH, *et al.*: Genomes of evolutionarily divergent members of the human T-cell leukemia virus family (HTLV-I and HTLV-II) are highly conserved, especially in pX. *Proc Natl Acad Sci U S A*. 1984; 81(14): 4544–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Gallo RC, Sarin PS, Gelmann EP, *et al.*: Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). *Science*. 1983; 220(4599): 865–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Wain-Hobson S, Sonigo P, Danos O, *et al.*: Nucleotide sequence of the AIDS virus, LAV. *Cell*. 1985; 40(1): 9–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Muesing MA, Smith DH, Cabradilla CD, *et al.*: Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. *Nature*. 1985; 313(6002): 450–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Ratner L, Haseltine W, Patarca R, *et al.*: Complete nucleotide sequence of the AIDS virus, HTLV-III. *Nature*. 1985; 313(6000): 277–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Ratner L, Gallo RC, Wong-Staal F: HTLV-III, LAV, ARV are variants of same AIDS virus. *Nature*. 1985; 313(6004): 636–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Gallo RC, Montagnier L: The chronology of AIDS research. *Nature*. 1987; 326(6112): 435–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Sodroski J, Rosen C, Wong-Staal F, *et al.*: Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. *Science*. 1985; 227(4683): 171–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Sodroski J, Patarca R, Rosen C, *et al.*: Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. *Science*. 1985; 229(4708): 74–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Sodroski J, Rosen C, Goh WC, *et al.*: A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. *Science*. 1985; 228(4706): 1430–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Feinberg MB, Jarrett RF, Aldovini A, *et al.*: HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. *Cell*. 1986; 46(6): 807–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Sodroski J, Goh WC, Rosen C, *et al.*: A second post-transcriptional trans-activator gene required for HTLV-III replication. *Nature*. 1986; 321(6068): 412–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Burkitt DP: Epidemiology of Burkitt's lymphoma. *Proc R Soc Med*. 1971; 64(9): 909–10.
[PubMed Abstract](#) | [Free Full Text](#)
 30. Thorley-Lawson DA, Allday MJ: The curious case of the tumour virus: 50 years of Burkitt's lymphoma. *Nat Rev Microbiol*. 2008; 6(12): 913–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. *Virology*. 2009; 384(2): 260–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Boshart M, Gissmann L, Ikenberg H, *et al.*: A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. *EMBO J*. 1984; 3(5): 1151–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Hjalgrim H, Friborg J, Melbye M: The epidemiology of EBV and its association with malignant disease. Ann Arvin GC-F, Edward Mocarski, Patrick S. Moore, Bernard Roizman, Richard Whitley, and Koichi Yamanishi., editor. UK: Cambridge University Press; 2007.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Schaefer BC, Strominger JL, Speck SH: Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. *Proc Natl Acad Sci U S A*. 1995; 92(23): 10565–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Einsiedel L, Spelman T, Goeman E, *et al.*: Clinical associations of Human T-Lymphotropic Virus type 1 infection in an indigenous Australian population. *PLoS Negl Trop Dis*. 2014; 8(1): e2643.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. **F** Malik B, Taylor GP: Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom. *Br J Haematol*. 2018.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 37. Villeneuve PJ, Mao Y: Lifetime probability of developing lung cancer, by smoking status, Canada. *Can J Public Health*. 1994; 85(6): 385–8.
[PubMed Abstract](#)
 38. Gallo RC, Willems L, Tagaya Y: Time to Go Back to the Original Name. *Front Microbiol*. 2017; 8: 1800.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Yodoi J, Takatsuki K, Masuda T: Letter: Two cases of T-cell chronic lymphocytic leukemia in Japan. *N Engl J Med*. 1974; 290(10): 572–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Gessain A, Cassar O: Epidemiological Aspects and World Distribution of HTLV-1 Infection. *Front Microbiol*. 2012; 3: 388.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Li HC, Fujiyoshi T, Lou H, *et al.*: The presence of ancient human T-cell lymphotropic virus type I provirus DNA in an Andean mummy. *Nat Med*. 1999; 5(12): 1428–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. **F** Igakura T, Stinchcombe JC, Goon PK, *et al.*: Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. *Science*. 2003; 299(5613): 1713–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 43. Kaul DR, Taranto S, Alexander C, *et al.*: Donor screening for human T-cell lymphotropic virus 1/2: changing paradigms for changing testing capacity. *Am J Transplant*. 2010; 10(2): 207–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Gessain A, Yanagihara R, Franchini G, *et al.*: Highly divergent molecular variants of human T-lymphotropic virus type I from isolated populations in Papua New Guinea and the Solomon Islands. *Proc Natl Acad Sci U S A*. 1991; 88(17): 7694–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Cassar O, Einsiedel L, Afonso PV, *et al.*: Human T-cell lymphotropic virus type 1 subtype C molecular variants among indigenous australians: new insights into the molecular epidemiology of HTLV-1 in Australo-Melanesia. *PLoS Negl Trop Dis*. 2013; 7(9): e2418.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Edwards D, Fenizia C, Gold H, *et al.*: Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence. *Viruses*. 2011; 3(6): 861–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. **F** Einsiedel LJ, Pham H, Woodman RJ, *et al.*: The prevalence and clinical associations of HTLV-1 infection in a remote Indigenous community. *Med J Aust*. 2016; 205(7): 305–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 48. Uchiyama T, Yodoi J, Sagawa K, *et al.*: Adult T-cell leukemia: clinical and hematologic features of 16 cases. *Blood*. 1977; 50(3): 481–92.
[PubMed Abstract](#)
 49. Montgomery RD, Cruickshank EK, Robertson WB, *et al.*: Clinical and Pathological Observations on Jamaican Neuropathy; a Report on 206 Cases. *Brain*. 1964; 87: 425–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Gessain A, Barin F, Vernant JC, *et al.*: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. *Lancet*. 1985; 2(8452): 407–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Osame M, Usuku K, Izumo S, *et al.*: HTLV-I associated myelopathy, a new clinical entity. *Lancet*. 1986; 1(8488): 1031–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Watanabe T: HTLV-1-associated diseases. *Int J Hematol*. 1997; 66(3): 257–78.
[PubMed Abstract](#)
 53. Martin F, Taylor GP, Jacobson S: Inflammatory manifestations of HTLV-1 and their therapeutic options. *Expert Rev Clin Immunol*. 2014; 10(11): 1531–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Mochizuki M, Watanabe T, Yamaguchi K, *et al.*: Uveitis associated with human T-cell lymphotropic virus type I. *Am J Ophthalmol*. 1992; 114(2): 123–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Kamoi K, Mochizuki M: HTLV-1 uveitis. *Front Microbiol*. 2012; 3: 270.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. **F** Einsiedel L, Pham H, Wilson K, *et al.*: Human T-Lymphotropic Virus type 1c subtype proviral loads, chronic lung disease and survival in a prospective cohort of Indigenous Australians. *PLoS Negl Trop Dis*. 2018; 12(3): e0006281.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 57. Kawano F, Tsuda H, Yamaguchi K, *et al.*: Unusual clinical courses of adult T-cell leukemia in siblings. *Cancer*. 1984; 54(1): 131–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Yamaguchi K, Nishimura H, Kohrogi H, *et al.*: A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases. *Blood*. 1983; 62(4): 758–66.
[PubMed Abstract](#)
 59. Yamaguchi K, Yoshioka R, Kiyokawa T, *et al.*: Lymphoma type adult T-cell leukemia—a clinicopathologic study of HTLV related T-cell type malignant

- lymphoma. *Hematol Oncol*. 1986; **4**(1): 59–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Takatsuki K: Adult T-cell leukemia. *Intern Med*. 1995; **34**(10): 947–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Miyoshi I, Yoshimoto S, Kubonishi I, *et al.*: Transformation of normal human cord lymphocytes by co-cultivation with a lethally irradiated human T-cell line carrying type C virus particles. *Gan*. 1981; **72**(6): 997–8.
[PubMed Abstract](#)
 62. Böhnlein E, Siekevitz M, Ballard DW, *et al.*: Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins. *J Virol*. 1989; **63**(4): 1578–86.
[PubMed Abstract](#) | [Free Full Text](#)
 63. Yoshida M, Inoue J, Fujisawa J, *et al.*: Molecular mechanisms of regulation of HTLV-1 gene expression and its association with leukemogenesis. *Genome*. 1989; **31**(2): 662–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Wano Y, Feinberg M, Hosking JB, *et al.*: Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth. *Proc Natl Acad Sci U S A*. 1988; **85**(24): 9733–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Felber BK, Paskalis H, Kleinman-Ewing C, *et al.*: The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. *Science*. 1985; **229**(4714): 675–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Ballard DW, Böhnlein E, Lowenthal JW, *et al.*: HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. *Science*. 1988; **241**(4873): 1652–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Ruben S, Poteat H, Tan TH, *et al.*: Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product. *Science*. 1988; **241**(4861): 89–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Xiao G, Cvijic ME, Fong A, *et al.*: Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. *EMBO J*. 2001; **20**(23): 6805–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Chu ZL, Shin YA, Yang JM, *et al.*: IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1. *J Biol Chem*. 1999; **274**(22): 15297–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Harhaj EW, Sun SC: IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. *J Biol Chem*. 1999; **274**(33): 22911–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Jin DY, Giordano V, Kibler KV, *et al.*: Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma. *J Biol Chem*. 1999; **274**(25): 17402–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Nerenberg M, Hinrichs SH, Reynolds RK, *et al.*: The tat gene of human T-lymphotropic virus type I induces mesenchymal tumors in transgenic mice. *Science*. 1987; **237**(4820): 1324–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Kitajima I, Shinohara T, Bilakovics J, *et al.*: Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. *Science*. 1992; **258**(5089): 1792–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Shirinian M, Kambris Z, Hamadeh L, *et al.*: A Transgenic *Drosophila melanogaster* Model To Study Human T-Lymphotropic Virus Oncoprotein Tax-1 Driven Transformation *In Vivo*. *J Virol*. 2015; **89**(15): 8092–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 75. Wu L, Zhang H, Jiang Y, *et al.*: Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. *Proc Natl Acad Sci U S A*. 2018; **115**(19): E4453–E62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Hasegawa H, Sawa H, Lewis MJ, *et al.*: Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. *Nat Med*. 2006; **12**(4): 466–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Raval GU, Bidoia C, Forlani G, *et al.*: Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. *Retrovirology*. 2015; **12**: 59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. Gaudray G, Gachon F, Basbous J, *et al.*: The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. *J Virol*. 2002; **76**(24): 12813–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. Matsuoka M, Green PL: The HBZ gene, a key player in HTLV-1 pathogenesis. *Retrovirology*. 2009; **6**: 71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Matsuoka M, Jeang KT: Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene*. 2011; **30**(12): 1379–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 81. Matsuoka M, Yasunaga J: Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. *Curr Opin Virol*. 2013; **3**(6): 684–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Miyazato P, Matsuoka M: Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy *in vivo*. *Int Immunol*. 2014; **26**(8): 419–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Ma G, Yasunaga J, Matsuoka M: Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis. *Retrovirology*. 2016; **13**: 16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Satou Y, Yasunaga J, Yoshida M, *et al.*: HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. *Proc Natl Acad Sci U S A*. 2006; **103**(3): 720–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Zhao T, Satou Y, Sugata K, *et al.*: HTLV-1 bZIP factor enhances TGF- β signaling through p300 coactivator. *Blood*. 2011; **118**(7): 1865–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 86. Toulza F, Nosaka K, Takiguchi M, *et al.*: FoxP3⁺ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. *Int J Cancer*. 2009; **125**(10): 2375–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 87. Satou Y, Yasunaga J, Zhao T, *et al.*: HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation *in vivo*. *PLoS Pathog*. 2011; **7**(2): e1001274.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 88. Satou Y, Utsunomiya A, Tanabe J, *et al.*: HTLV-1 modulates the frequency and phenotype of FoxP3⁺CD4⁺ T cells in virus-infected individuals. *Retrovirology*. 2012; **9**: 46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 89. Yamamoto-Taguchi N, Satou Y, Miyazato P, *et al.*: HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. *PLoS Pathog*. 2013; **9**(9): e1003630.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 90. Hanon E, Goon P, Taylor GP, *et al.*: High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. *Blood*. 2001; **98**(3): 721–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 91. Ma G, Yasunaga J, Fan J, *et al.*: HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. *Oncogene*. 2013; **32**(36): 4222–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. Yasuma K, Yasunaga J, Takemoto K, *et al.*: HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). *PLoS Pathog*. 2016; **12**(1): e1005372.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 93. Kinoshita H, Yasunaga J, Shimura K, *et al.*: HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. *PLoS Pathog*. 2017; **13**(1): e1006120.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 94. Sugata K, Yasunaga J, Kinoshita H, *et al.*: HTLV-1 Viral Factor HBZ Induces CCR4 to Promote T-cell Migration and Proliferation. *Cancer Res*. 2016; **76**(17): 5068–79.
[PubMed Abstract](#) | [Publisher Full Text](#)
 95. Tamiya S, Matsuoka M, Etoh K, *et al.*: Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. *Blood*. 1996; **88**(8): 3065–73.
[PubMed Abstract](#)
 96. Miyazaki M, Yasunaga J, Taniguchi Y, *et al.*: Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5' long terminal repeat during oncogenesis. *J Virol*. 2007; **81**(11): 5714–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 97. Durkin K, Rosewick N, Artesi M, *et al.*: Characterization of novel Bovine Leukemia Virus (BLV) antisense transcripts by deep sequencing reveals constitutive expression in tumors and transcriptional interaction with viral microRNAs. *Retrovirology*. 2016; **13**(1): 33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 98. Zapata JC, Campilongo F, Barclay RA, *et al.*: The Human Immunodeficiency Virus 1 ASP RNA promotes viral latency by recruiting the Polycomb Repressor Complex 2 and promoting nucleosome assembly. *Virology*. 2017; **506**: 34–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 99. Cereseto A, Mulloy JC, Franchini G: Insights on the pathogenicity of human T-lymphotropic/leukemia virus types I and II. *J Acquir Immune Defic Syndr Hum Retroviro*. 1996; **13** Suppl 1: S69–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 100. Yin H, Kannan P, Dissinger N, *et al.*: Human T-cell leukemia virus type 2 antisense viral protein 2 is dispensable for *in vitro* immortalization but functions to repress early virus replication *in vivo*. *J Virol*. 2012; **86**(16): 8412–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 101. Panfil AR, Dissinger NJ, Howard CM, *et al.*: Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia

- Virus Type 1 Pathogenesis.** *J Virol.* 2016; 90(7): 3760–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
102. Billman MR, Rueda D, Bangham CRM: **Single-cell heterogeneity and cell-cycle-related viral gene bursts in the human leukaemia virus HTLV-1 [version 2; referees: 2 approved, 1 approved with reservations].** *Wellcome Open Res.* 2017; 2: 87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 103. Mahgoub M, Yasunaga JI, Iwami S, *et al.*: **Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells.** *Proc Natl Acad Sci U S A.* 2018; 115(6): E1269–E78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 104. Jacobson S, Reuben JS, Streilein RD, *et al.*: **Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.** *J Immunol.* 1991; 146(4): 1155–62.
[PubMed Abstract](#)
 105. Goon PK, Hanon E, Igakura T, *et al.*: **High frequencies of Th1-type CD4+ T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.** *Blood.* 2002; 99(9): 3335–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
 106. Tosi G, Forlani G, Andresen V, *et al.*: **Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.** *J Virol.* 2011; 85(20): 10719–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 107. Forlani G, Abdallah R, Accolla RS, *et al.*: **The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF- κ B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.** *J Virol.* 2016; 90(7): 3708–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 108. Leal FE, Menezes SM, Costa EAS, *et al.*: **Comprehensive Antiretroviral Restriction Factor Profiling Reveals the Evolutionary Imprint of the ex Vivo and in Vivo IFN- β Response in HTLV-1-Associated Neuroinflammation.** *Front Microbiol.* 2018; 9: 985.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 109. **F** Kataoka K, Nagata Y, Kitanaka A, *et al.*: **Integrated molecular analysis of adult T cell leukemia/lymphoma.** *Nat Genet.* 2015; 47(11): 1304–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 110. Derse D, Crise B, Li Y, *et al.*: **Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses.** *J Virol.* 2007; 81(12): 6731–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 111. Meekings KN, Leipzig J, Bushman FD, *et al.*: **HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP.** *PLoS Pathog.* 2008; 4(3): e1000027.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 112. **F** Rosewick N, Durkin K, Artesi M, *et al.*: **Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis.** *Nat Commun.* 2017; 8: 15264.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 113. **F** Melamed A, Yaguchi H, Miura M, *et al.*: **The human leukemia virus HTLV-1 alters the structure and transcription of host chromatin in cis.** *eLife.* 2018; 7: pii: e36245.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 114. **F** Satou Y, Miyazato P, Ishihara K, *et al.*: **The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome.** *Proc Natl Acad Sci U S A.* 2016; 113(11): 3054–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 115. Ijichi S, Izumo S, Eiraku N, *et al.*: **An autoaggressive process against bystander tissues in HTLV-1-infected individuals: a possible pathomechanism of HAM/TSP.** *Med Hypotheses.* 1993; 41(6): 542–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 116. **F** Baratella M, Forlani G, Raval GU, *et al.*: **Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).** *PLoS Negl Trop Dis.* 2017; 11(1): e0005285.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 117. Sato T, Coler-Reilly A, Utsunomiya A, *et al.*: **CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.** *PLoS Negl Trop Dis.* 2013; 7(10): e2479.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 118. Tendler CL, Greenberg SJ, Burton JD, *et al.*: **Cytokine induction in HTLV-1 associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis.** *J Cell Biochem.* 1991; 46(4): 302–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 119. Azimi N, Mariner J, Jacobson S, *et al.*: **How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis?** *AIDS Res Hum Retroviruses.* 2000; 16(16): 1717–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 120. Azimi N, Nagai M, Jacobson S, *et al.*: **IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients.** *Proc Natl Acad Sci U S A.* 2001; 98(25): 14559–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 121. Azimi N, Jacobson S, Leist T, *et al.*: **Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor.** *J Immunol.* 1999; 163(7): 4064–72.
[PubMed Abstract](#)
 122. Lando Z, Sarin P, Megson M, *et al.*: **Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor.** *Nature.* 1983; 305(5936): 733–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 123. Uchiyama T, Broder S, Waldmann TA: **A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.** *J Immunol.* 1981; 126(4): 1393–7.
[PubMed Abstract](#)
 124. Berkowitz JL, Janik JE, Stewart DM, *et al.*: **Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.** *Clin Immunol.* 2014; 155(2): 176–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 125. Waldmann TA: **Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.** *J Clin Immunol.* 2007; 27(1): 1–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
 126. Zhang M, Yao Z, Garmestani K, *et al.*: **Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.** *Cancer Biother Radiopharm.* 2009; 24(3): 303–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 127. Zhang Z, Zhang M, Garmestani K, *et al.*: **Effective treatment of a murine model of adult T-cell leukemia using ²¹¹At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.** *Blood.* 2006; 108(3): 1007–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 128. Ishida T, Iida S, Akatsuka Y, *et al.*: **The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma.** *Clin Cancer Res.* 2004; 10(22): 7529–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
 129. **F** Ishida T, Jo T, Takemoto S, *et al.*: **Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.** *Br J Haematol.* 2015; 169(5): 672–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 130. Ishida T, Joh T, Uike N, *et al.*: **Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.** *J Clin Oncol.* 2012; 30(8): 837–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 131. Ishida T, Utsunomiya A, Iida S, *et al.*: **Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.** *Clin Cancer Res.* 2003; 9(10 Pt 1): 3625–34.
[PubMed Abstract](#)
 132. Ishii T, Ishida T, Utsunomiya A, *et al.*: **Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.** *Clin Cancer Res.* 2010; 16(5): 1520–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 133. Ishida T, Jo T, Takemoto S, *et al.*: **Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.** *Br J Haematol.* 2019; 184(3): 479–483.
[PubMed Abstract](#) | [Publisher Full Text](#)
 134. Ishida T, Utsunomiya A, Jo T, *et al.*: **Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.** *Cancer Sci.* 2017; 108(10): 2022–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 135. **F** Kawano N, Kuriyama T, Sonoda KH, *et al.*: **Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).** *Intern Med.* 2016; 55(11): 1439–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 136. Yamamoto K, Utsunomiya A, Tobinai K, *et al.*: **Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.** *J Clin Oncol.* 2010; 28(9): 1591–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 137. Ishida T, Ito A, Sato F, *et al.*: **Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.** *Cancer Sci.* 2013; 104(5): 647–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 138. Brown M, Bellon M, Nicot C: **Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-1-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.** *Blood.* 2007; 109(4): 1653–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 139. Mahieux R, Pise-Masison C, Gessain A, *et al.*: **Arsenic trioxide induces apoptosis**

- in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. *Blood*. 2001; **98**(13): 3762–9. [PubMed Abstract](#) | [Publisher Full Text](#)
140. Bazarbachi A, Suarez F, Fields P, *et al.*: **How I treat adult T-cell leukemia/lymphoma.** *Blood*. 2011; **118**(7): 1736–45. [PubMed Abstract](#) | [Publisher Full Text](#)
 141. El Hajj H, El-Sabban M, Hasegawa H, *et al.*: **Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.** *J Exp Med*. 2010; **207**(13): 2785–92. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 142. Okayama A, Stuver S, Matsuoka M, *et al.*: **Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers.** *Int J Cancer*. 2004; **110**(4): 621–5. [PubMed Abstract](#) | [Publisher Full Text](#)
 143. Bangham CR, Cook LB, Melamed A: **HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection.** *Semin Cancer Biol*. 2014; **26**: 89–98. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 144. Cook LB, Melamed A, Niederer H, *et al.*: **The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma.** *Blood*. 2014; **123**(25): 3925–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 145. **F** Gillet NA, Cook L, Laydon DJ, *et al.*: **Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality *in vivo*.** *PLoS Pathog*. 2013; **9**(4): e1003263. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 146. **F** Turpin J, Alais S, Marçais A, *et al.*: **Whole body clonality analysis in an aggressive STLV-1 associated leukemia (ATLL) reveals an unexpected clonal complexity.** *Cancer Lett*. 2017; **389**: 78–85. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 147. Macnamara A, Rowan A, Hilburn S, *et al.*: **HLA class I binding of HBZ determines outcome in HTLV-1 infection.** *PLoS Pathog*. 2010; **6**(9): e1001117. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 148. Sugata K, Yasunaga J, Mitobe Y, *et al.*: **Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor.** *Blood*. 2015; **126**(9): 1095–105. [PubMed Abstract](#) | [Publisher Full Text](#)
 149. Tsukasaki K, Maeda T, Arimura K, *et al.*: **Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature.** *Bone Marrow Transplant*. 1999; **23**(1): 87–9. [PubMed Abstract](#) | [Publisher Full Text](#)
 150. Obama K, Tara M, Sao H, *et al.*: **Allogeneic bone marrow transplantation as a treatment for adult T-cell leukemia.** *Int J Hematol*. 1999; **69**(3): 203–5. [PubMed Abstract](#)
 151. Bangham CR, Araujo A, Yamano Y, *et al.*: **HTLV-1-associated myelopathy/tropical spastic paraparesis.** *Nat Rev Dis Primers*. 2015; **1**: 15012. [PubMed Abstract](#) | [Publisher Full Text](#)
 152. Yamauchi J, Coler-Reilly A, Sato T, *et al.*: **Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8⁺ and CD4⁺ T cells to treat associated myelopathy.** *J Infect Dis*. 2015; **211**(2): 238–48. [PubMed Abstract](#) | [Publisher Full Text](#)
 153. **F** Sato T, Coler-Reilly ALG, Yagishita N, *et al.*: **Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.** *N Engl J Med*. 2018; **378**(6): 529–38. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 154. Nata T, Basheer A, Cocchi F, *et al.*: **Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum.** *J Biol Chem*. 2015; **290**(37): 22338–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 155. Massoud R, Enose-Akahata Y, Tagaya Y, *et al.*: **Common γ -chain blocking peptide reduces *in vitro* immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.** *Proc Natl Acad Sci U S A*. 2015; **112**(35): 11030–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 156. Ju W, Zhang M, Jiang JK, *et al.*: **CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.** *Blood*. 2011; **117**(6): 1938–46. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 157. Martin F, Tagaya Y, Gallo R: **Time to eradicate HTLV-1: an open letter to WHO.** *Lancet*. 2018; **391**(10133): 1893–4. [PubMed Abstract](#) | [Publisher Full Text](#)
 158. Moriuchi H, Masuzaki H, Doi H, *et al.*: **Mother-to-child transmission of human T-cell lymphotropic virus type 1.** *Pediatr Infect Dis J*. 2013; **32**(2): 175–7. [PubMed Abstract](#) | [Publisher Full Text](#)
 159. Bomford R, Kazanji M, De The G: **Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects.** *AIDS Res Hum Retroviruses*. 1996; **12**(5): 403–5. [PubMed Abstract](#) | [Publisher Full Text](#)
 160. Shida H, Tochikura T, Sato T, *et al.*: **Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.** *EMBO J*. 1987; **6**(11): 3379–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 161. Dezzutti CS, Frazier DE, Huff LY, *et al.*: **Subunit vaccine protects Macaca nemestrina (pig-tailed macaque) against simian T-cell lymphotropic virus type I challenge.** *Cancer Res*. 1990; **50**(17 Suppl): 5687S–91S. [PubMed Abstract](#)
 162. Franchini G, Tartaglia J, Markham P, *et al.*: **Highly attenuated HTLV type I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits.** *AIDS Res Hum Retroviruses*. 1995; **11**(2): 307–13. [PubMed Abstract](#) | [Publisher Full Text](#)
 163. Mahieux R: **A vaccine against HTLV-1 HBZ makes sense.** *Blood*. 2015; **126**(9): 1052–3. [PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Roberto S Accolla**

Department of Medicine and Surgery, University of Insubria, Varese, Italy

Competing Interests: No competing interests were disclosed.

2. **Anne Van den Broeke**

¹ Université Libre de Bruxelles (ULB), Experimental Hematology, Institut Jules Bordet, Brussels, Belgium

² Unit of Animal Genomics, GIGA, Université de Liège (ULiège), Liège, Belgium

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research